The EuroSIDA Study: Regional Differences in the HIV-1 Epidemic and Treatment Response to Antiretroviral Therapy among HIV-infected Patients across Europe - A Review of Published Results

HIV and people over 50 years old in Europe

“…Hence, in order to achieve universal access to HIV/AIDS prevention, treatment, care and support -and sexual behaviour in Europeit is important that the clinical outcomes of older people are not overlooked. One study, EuroSIDA, a pan-European observational study that follows 14 265 HIV-infected patients from 31 European countries, Israel and Argentina, is already showing substantial regional differences in demographic and clinical characteristics of people living with HIV [21].…”

Respuesta virológica e inmunológica a la terapia anti-retroviral en pacientes portadores de infección por VIH atendidos en una red de salud académica de Chile

“…Cabe destacar que en nuestro estudio, las mujeres alcanzaron similares recuentos de LT CD4+ que los hombres, lo que difiere de otras publicaciones 7 . Los pacientes alcanzaron carga viral indetectable (< 50 copias ARN/ml) en 86 y 80% de los casos a las 96 y 144 semanas, respectivamente, lo que es enteramente comparable e incluso superior a los resultados reportados por otros autores 3, [8][9][10][11][12] . En resumen, reportamos una excelente respuesta inmunológica y virológica a TARV en una cohorte de pacientes portadores de VIH atendidos en una Red de Salud académica con un seguimiento a 144 semanas.…”

Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

“…Patients receiving concomitant d4T and isoniazid have a greatly increased risk of peripheral neuropathy, compared with those receiving only d4T [33]. Recent findings from the D:A:D study suggest avoiding use of d4T in patients with a high risk of end‐stage liver disease, which is relevant in the context of a high prevalence of HCV coinfection and alcohol consumption [22,34]. However, evidence from Eastern Europe is scarce.…”

“…EuroSIDA is a prospective observational cohort study of 18 786 HIV‐1‐infected patients from 107 clinics in 37 countries (Europe, Israel and Argentina). The details of the cohort have been presented elsewhere [21,22]. The cohort study aims to include a representative sample of the HIV‐positive patients followed in the participating clinics.…”

“…To compare d4T utilization across EuroSIDA, six regions were established according to the country of residence of the patient, as in previous EuroSIDA studies [22]: Southern Europe (South): Greece, Italy, Israel, Portugal and Spain; West Central Europe (West Central): Austria, Belgium, France, south Germany, Luxembourg and Switzerland; Northern Europe (North): Denmark, Finland, north Germany, Ireland, the Netherlands, Norway, Sweden and the UK; East Central Europe (East Central): Bulgaria, Croatia, the Czech Republic, Hungary, Poland, Romania, Serbia and Slovakia; Eastern Europe (East): Belarus, Estonia, Latvia, Lithuania, the Russian Federation and the Ukraine; and Argentina.…”